This research is Trending!
July 20, 2026JAMA
Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy
Key result
The 2026 dyslipidemia guideline newly qualifies ~14% of US adults for primary prevention statins vs 2018.
- n=4,366
Why the study?
The 2026 AHA/ACC/multisociety dyslipidemia guideline issued new recommendations on ASCVD risk estimation and statin eligibility for primary prevention, requiring assessment of its population health impact.
Does the 2026 dyslipidemia guideline change eligibility for primary prevention statin therapy compared to the 2018 guideline in US adults without known ASCVD?
Study Design
Type
Cross-Sectional (n=4,366)
Structured PICO
Does the 2026 dyslipidemia guideline change eligibility for primary prevention statin therapy compared to the 2018 guideline in US adults without known ASCVD?
P
Population
4,366 nonpregnant US adults aged 30 to 79 years without known ASCVD, representing 154.5 million individuals, assessed for statin eligibility.
E
Exposure
Application of the 2026 American Heart Association/American College of Cardiology/multisociety dyslipidemia guideline criteria for primary prevention statin therapy
C
Comparator
Application of the 2018 lipid guideline criteria
O
Outcome
Changes in eligibility for primary prevention statin therapy
The 2026 dyslipidemia guideline substantially expands the US population recommended for primary prevention statin therapy, predominantly by including younger and lower-risk individuals.
Discussion
No takes yet. Share an insight, caveat, or question.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Observational evidence suggests the longer people are exposed to high levels of inflammatory cholesterol molecules, the greater their downstream risks of heart attacks and strokes are. Unfortunately, we do not have randomized clinical trials for low-risk people 30 years out that would directly support this new understanding of how risk builds more gradually over the years—because such trials are expensive, and we need to wait decades for the answer.”
“Under the new guidelines, about 10% of Americans in their 30s and 40% in their 40s are recommended statins. By the time people are in their 50s, however, that number goes up to around 80%, and for people in their 60s, it's 85%. And over 90% of all people in their 70s are recommended statins under today's guidelines.”
Implication
Substantially expands statin eligibility to 56.6% of US adults; leaves open net benefit for newly eligible lower-risk groups.
Abstract
Importance: The 2026 American Heart Association/American College of Cardiology/multisociety guideline on the management of dyslipidemia issued new recommendations on estimating atherosclerotic cardiovascular disease (ASCVD) risk and on populations eligible for statins for primary prevention. Objective: To assess the population health impact of the 2026 guideline on primary prevention statin therapy. Design, Setting, and Participants: Nationally representative, cross-sectional sample of nonpregnant adults aged 30 to 79 years without known ASCVD, who participated in the National Health and Nutrition Examination Survey from 2017 to 2023. Data were analyzed from March to May 2026. Main Outcomes and Measures: Changes in eligibility for primary prevention statin therapy, comparing the 2026 and 2018 lipid guidelines. Results: The weighted sample included 4366 NHANES participants representative of 154.5 million US adults (weighted mean age, 51 years; 52.0% female). Of these, 5.5% (95% CI, 4.7%-6.6%) had untreated low-density lipoprotein cholesterol below 70 mg/dL, 17.8% (95% CI, 16.3%-19.5%) reported currently taking statins, and 8.6% (95% CI, 7.6%-9.8%) met criteria for statin eligibility independent of ASCVD risk estimation based on a low-density lipoprotein cholesterol of 190 mg/dL or greater, diabetes, or chronic kidney disease. The remaining 68.0% of patients (95% CI, 65.9%-70.0%) met guideline criteria for using ASCVD risk estimation to guide statin decisions. In total, an estimated 87.5 million (56.6% [95% CI, 54.2%-58.9%]) nonpregnant US adults aged 30 to 79 years were statin eligible based on the 2026 guideline, including 21.5 million (13.9% [95% CI, 12.5%-15.5%]) who were newly statin eligible. More than 93% of adults aged 70 to 79 years and 85% of adults aged 60 to 69 years are eligible for primary prevention statin therapy compared with 11% of adults aged 30 to 39 years. Newly statin-eligible populations were largely younger and lower risk than populations previously recommended statin therapy (mean estimated 10-year ASCVD risk, 3.1% [95% CI, 2.7%-3.5%] for newly statin-eligible individuals vs 6.1% [95% CI, 5.8%-6.4%] for individuals previously eligible for statin therapy). Conclusions and Relevance: The 2026 dyslipidemia guideline substantially expands the US population recommended for primary prevention statin therapy, predominantly in lower-risk individuals.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Anderson et al. (2026) conducted a cross-sectional in Dyslipidemia (n=4,366). 2026 dyslipidemia guideline vs. 2018 lipid guidelines was evaluated on Changes in eligibility for primary prevention statin therapy. The 2026 dyslipidemia guideline expanded primary prevention statin eligibility to 56.6% of US adults aged 30 to 79 years, rendering an additional 13.9% (21.5 million) newly eligible compared to 2018.